Abstract
After more than 20 years of clinical use, methotrexate has shown itself to be an effective and versatile chemotherapeutic agent. By its antifolate action, it impairs the synthesis of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), an action that accounts for its clinical usefulness as well as its toxicity.
Chapter PDF
References
CLARYSSE, A. M., et al.: Pulmonary disease complicating intermittent therapy with methotrexate. JAMA,209: 1861, 1969.
HERSH, E. M., et al.: Hepatotoxic effects of methotrexate. Cancer,19: 600, 1966.
RAGAB, A. H., et al.: Osteoporotic fractures secondary to methotrexate therapy of acute leukemia in remission. Cancer,25: 580, 1970.
KAY, H. E. M., et al.: Encephalopathy in acute leukemia associated with methotrexate therapy. Arch Dis Child, 47: 344, 1972.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1973 Ontario Cancer Treatment and Research Foundation
About this chapter
Cite this chapter
Freedman, M.H. (1973). Methotrexate Toxicity. In: Godden, J.O. (eds) Cancer in Childhood. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-2070-8_35
Download citation
DOI: https://doi.org/10.1007/978-1-4684-2070-8_35
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-2072-2
Online ISBN: 978-1-4684-2070-8
eBook Packages: Springer Book Archive